Evidence map›Paper›PMID 29581162›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2018

Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.

Andrea L Schaffer, Nicholas A Buckley, Louisa Degenhardt, Briony Larance, Rose Cairns, Timothy A Dobbins, Sallie-Anne Pearson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Andrea L SchafferCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU andrea.schaffer@unsw.edu.au.
Nicholas A BuckleyCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
Louisa DegenhardtCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
Briony LaranceCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
Rose CairnsCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
Timothy A DobbinsCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
Sallie-Anne PearsonCentre for Big Data Research in Health (Schaffer, Pearson), University of New South Wales; School of Medical Sciences (Buckley), University of Sydney; National Drug and Alcohol Research Centre (Degenhardt, Larance, Dobbins), University of New South Wales, Sydney, AU; New South Wales Poisons Information Centre (Cairns), Children's Hospital at Westmead, Westmead, AU.
University of Sydney · AUChildren's Hospital at Westmead · AUPearson (United States) · USUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAustralia introduced tamper-resistant controlled-release (CR) oxycodone in April 2014. We quantified the impact of the reformulation on dispensing, switching and poisonings.

methodsWe performed interrupted time-series analyses using population-representative national dispensing data from 2012 to 2016. We measured dispensing of oxycodone CR (≥ 10 mg), discontinuation of use of strong opioids and switching to other strong opioids after the reformulation compared with a historical control period. Similarly, we compared calls about intentional opioid poisoning using data from a regional poisons information centre.

resultsAfter the reformulation, dispensing decreased for 10-30 mg (total level shift -11.1%, 95% confidence interval [CI], -17.2% to -4.6%) and 40-80 mg oxycodone CR (total level shift -31.5%, 95% CI -37.5% to -24.9%) in participants less than 65 years of age but was unchanged in people 65 years of age or older. Compared with the previous year, discontinuation of use of strong opioids did not increase (adjusted hazard ratio [HR] 0.95, 95% CI 0.91 to 1.00), but switching to oxycodone/naloxone did increase (adjusted HR 1.54, 95% CI 1.32 to 1.79). Switching to morphine varied by age (

interpretationThe reformulation had a greater impact on opioid access patterns of people less than 65 years of age who were using higher strengths of oxycodone CR. This group has been identified as having an increased risk of problematic opioid use and warrants closer monitoring in clinical practice.

Indexed as

Drug CompoundingAdultAgedAged, 80 and overAnalgesics, OpioidAustraliaDelayed-Action PreparationsFemaleHumansInterrupted Time Series AnalysisLogistic ModelsMaleMiddle AgedOpioid-Related DisordersOxycodonePractice Patterns, Physicians'Analgesics, OpioidDelayed-Action PreparationsOxycodone

Identifiers

PMID29581162
PMCPMC5871439
OpenAlexW2791140527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.